CAR-T cell a potential platform for cancer therapy

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has emerged as a viable treatment for various types of cancers, including B-cell lymphoma and leukemia. CAR-T cells use genetically engineered T lymphocytes that are retargeted to destroy cancer cells using Chimeric Antigen Receptor (CAR). CARs are modular synthetic receptor that consists of three major components: (1) ectodomain, (2) transmembrane domain, and (3) endo-domain. This review discussed the evolution of CAR-T cell, the mechanism of CAR T-cell for cancer treatment, and the application of CAR T-cell therapy for different types of cancer such as lung cancer, breast cancer, ovarian cancer, renal cancer, prostate cancer, pancreatic cancer, and brain cancer. At the last, we have also discussed the clinical approach and patents of CAR-T cells.